Home » Duke Licenses NPM1 from Trovagene for AML Research, Testing

Duke Licenses NPM1 from Trovagene for AML Research, Testing

Dec 27, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted Duke University and Duke University Health Systems a non-exclusive license covering the use of the nucleophosmin protein (NPM1).

The agreement allows Duke to incorporate NPM1 into research and clinical testing services for acute myelogenous leukemia. The terms of the deal includes upfront payments and royalties. Further details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Bit of Uncertainty

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Effect of Sex

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Better Microbes

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

This Week in PNAS

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.

What's Popular?

In Diagnostics

  1. Myriad Genetics Signs Pricing Agreement With United Healthcare for Several Tests

  2. Interpace Diagnostics Closes $12.2M Public Offering

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.